Research programme: inflammatory pain therapeutic - Relevare
Alternative Names: CNSB 006Latest Information Update: 01 Sep 2015
At a glance
- Originator CNSBio
- Developer Relevare Pharmaceuticals
- Class Analgesics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Inflammatory pain
Most Recent Events
- 07 Oct 2008 Preclinical trials in Inflammatory pain in Australia (unspecified route)